MELBOURNE, Australia and LIÉGE, Belgium, Dec. 4, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a named patient (early access) program in the Netherlands for its investigational positron emission tomography (PET) imaging agent TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer.

Through this named patient program in the Netherlands (‘Leveren op Artsenverklaring’), physicians may seek individual access to TLX250-CDx for use in PET characterisation of renal masses as ccRCC. The first patient was dosed at Radboud University Medical Centre in Nijmegen, Netherlands.

The program follows the completion of Telix’s successful global Phase III ZIRCON study (Zirconium in Renal Cancer Oncology, ClinicalTrials.gov Identifier: NCT03849118), which reported positive results in November 2022, meeting all co-primary and secondary endpoints.1

Professor Dr. Peter Mulders from Radboud University Medical Centre (Netherlands), a Principal Investigator on Telix’s completed ZIRCON trial commented, "Continued access to this investigational imaging agent is critically important. The detection of ccRCC in the early stages of disease can often be challenging, and reliant on invasive biopsy and nephrectomy (kidney removal). It is therefore extremely good news that TLX250-CDx, which offers a non-invasive option – or ‘molecular biopsy’ – is now available in the Netherlands on a named patient basis."

Frédéric Fantino, Telix Medical Director for the Europe, Middle East and Africa (EMEA) region, added, "The first patient dosed in this European named patient program is a significant step for Telix to support continued unmet patient need and educate key opinion leaders on the potential of TLX250-CDx to change standard of care in the diagnosis and management of ccRCC. The ZIRCON study has shown this imaging agent to be highly sensitive and specific in the detection of ccRCC, where existing imaging techniques are sometimes inconclusive."

In the Netherlands, the use of a medicinal product in an individual patient prior to marketing authorisation and outside the context of a clinical trial is permitted in exceptional circumstances. Individual requests must be initiated by the treating physician and are evaluated by the Dutch Health Inspectorate (IGJ).

Telix is progressing towards a Biologics License Application (BLA) submission for TLX250-CDx with the United States Food and Drug Administration (FDA) and other equivalent applications with regulatory agencies in key commercial jurisdictions.

Physicians in Europe who may have eligible patients can email [email protected] for further information about TLX250-CDx named patient access.

For more information about ongoing clinical trials of TLX250-CDx, please visit https://telixpharma.com/our-portfolio/clinical-trials/

Telix’s Policy on Offering Compassionate Use to Investigational Medicines can be downloaded at the following link.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn.

TLX250-CDx has not received a marketing authorisation in any jurisdiction. Telix’s lead imaging product, gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection, has been approved by the FDA,2 by the Australian Therapeutic Goods Administration (TGA),3 and by Health Canada.4

Telix’s SENSEI® ultra-miniaturised robotic gamma probe is registered as a Class 1 device with the FDA, and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area for intra-operative detection of sentinel lymph nodes.5

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: [email protected]

Legal Notices

This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments.  Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website.

©2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).

1 Telix ASX disclosure 7 November 2022.
2 Telix ASX disclosure 20 December 2021.
3 Telix ASX disclosure 2 November 2021.
4 Telix ASX disclosure 14 October 2022.
5 Lightpoint Medical media release 20 January 2021.

Source : First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

XUZHOU, China, Dec. 3, 2023 /PRNewswire/ — In recent years, State Grid Xuzhou Power Supply Co., Ltd. has been committed to building and upgrading power grid in rural areas.

At 9 p.m. on November 28, Zhang Shuaishuai, an employee of State Grid Xuzhou Power Supply Co., Ltd., received a call for help and came to the chrysanthemum planting base of Jiangsu YiAn Flower Co., Ltd. to eliminate a fault of frequent tripping of air switches caused by line breaking and grounding, so that four electric hot air fans and 60+ lighting lamps in the greenhouse could be restored to use, and chrysanthemums would not be damaged.

"The greenhouse has been in use for a long time, and the heat preservation effect is not good. At night, the temperature in the greenhouse depends on these equipment, otherwise the chrysanthemums will be frostbitten in a large area," said Hu Qing, head of Jiangsu YiAn Flower Co., Ltd., clutching Zhang Shuaishuai’s hand.

It is reported that Hu Qing is a famous local "Chrysanthemum Fairy". Her base sells 30,000+ chrysanthemums a day, 90% of which are sold overseas, and whenever there is a power problem, the power supply company will come within 10 minutes to solve the problem.

In 2008, Hu Qing, a migrant worker, returned home and contracted 60 mu of land to build 20+ greenhouses to plant chrysanthemums. Because of inexperience, however, chrysanthemums were not growing well. "Only by controlling the key factors such as light, water, fertilizer and temperature, can the growth quality of chrysanthemum be guaranteed, and to achieve the above, electrification is the key." After investigation, Hu Qing decided to upgrade the existing greenhouse to electrified greenhouse.

In 2010, State Grid Xuzhou Power Supply Co., Ltd. set up a 250 KVA transformer and 900+ meters of MV and LV lines to send electricity to the field. Thanks to this, the greenhouse has added the equipment such as electric shutter machine, temperature control system, and water and fertilizer integrated irrigation machine, which shortens the growth cycle of chrysanthemum and increases its output. Around the Spring Festival of that year, the chrysanthemums in the greenhouse ushered in a bumper harvest, and Hu Qing earned nearly 200,000 yuan at one stroke.

Since then, Hu Qing has expanded the planting scale to 600 mu, built 50+ greenhouses and linked greenhouses, and 200+ steel frame greenhouses. Driven by her, the surrounding villagers have been engaged in chrysanthemum planting one after another. Caoqiao Town has formed a ten mile ecological corridor with Gudun Village as the core, with a chrysanthemum planting area of 3,000+ mu. In this process, State Grid Xuzhou Power Supply Co., Ltd. has strengthened the transformation of rural distribution network, built or transformed 50+ km of MV and LV lines, added 80+ distribution transformers, and used 40,000 KVA of electricity capacity.

In the past two years, with the help of the power supply company, Hu Qing has built drying production lines and fresh storage. Relying on the planting and processing system of "cooperatives + universities + farmers", Hu Qing developed 10+ series of products such as chrysanthemum tea, medicinal cosmetics and chrysanthemum essential oil, with an annual output value of about 50 million yuan.

Source : "Full Grid Electricity" Helps Open "Wealth Flower"

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SYDNEY, Dec. 4, 2023 /PRNewswire/ — Manhattan Associates Inc. (NASDAQ: MANH) has been recignised as an innovation leader, winning two major categories at the 2023 ABA100® Australian Business Awards for a second year in a row. The company received the Supply Chain Innovation Award for its Manhattan Active® Warehouse Management solution, while also winning the Cloud Innovation Award for its Manhattan Unified Commerce Active® Omni technology.

The 2023 ABA100® Supply Chain Innovation Award highlights groundbreaking advancements in supply chain management. Manhattan Active® Warehouse Management–a core component of the Manhattan Active Supply Chain suite–has been acknowledged as the standout in its field for its cabability to dynamically adapt to operational needs and highly customisable user interface. It benefits from regular, quarterly updates, ensuring it remains updated without affecting customisations, thereby eliminating the need for traditional upgrades.

Manhattan Active® Warehouse Management employs advanced, proprietary algorithms to enhance supply chain operations, speeding up the movement of goods and information. This results in seamless inventory, workforce, and storage coordination, and ensures compliance with industry standards.

"We’re delighted to receive the ABA100® award for Supply Chain Innovation at the Australian Business Awards 2023," stated Raghav Sibal, Managing Director, ANZ, at Manhattan Associates. "Our cloud-based solution, Manhattan Active® Warehouse Management, is at the forefront of technology, offering ongoing access to the latest features. It’s designed to scale responsively to retail sector demands, especially during peak periods. This intelligent, adaptable technology is built for expansion, integrating new innovations effortlessly."

In addition, Manhattan Associates was honoured with the Cloud Innovation Award for its Manhattan Active® Omni technology. This award recognises cloud solutions that offer innovative solutions to business challenges.

Manhattan Active® Omni is a unified, cloud-native application revolutionising selling, engagement, and fulfilment. Unique in its adaptability and scalability, it delivers profitable omnichannel customer experiences. It combines order management, inventory, fulfilment, customer engagement, and point of sale solutions in a current, expandable platform.

A new addition this year to Manhattan Active Omni is its integration with Google Merchant Center, announced at the annual Momentum conference. This integration, leveraging Google’s Content API for shopping, enables retailers using Manhattan Active Omni to offer more precise location- and product-specific delivery times on various Google platforms, including Search, YouTube, Maps, and Discover. This capability is critical as fast shipping speeds significantly influence buyer decisions. By linking Manhattan Active Omni with Google Merchant Center, Google’s Machine Learning models utilise Manhattan’s historical shipping data to generate more accurate delivery time estimates, enhancing customer experiences and conversions.

Raghav Sibal commented, "The integration of physical and digital retail is now seamless. Today’s omnichannel retailing offers a uniform experience across all customer touchpoints. Our unified cloud-based solutions are constantly evolving, streamlining processes for our clients’ benefit."

"We are proud that our Manhattan Active® Omni solution, now integrated with Google Merchant Center, is recognised by the Australian Business Awards for its cloud innovation. This solution is a reflection of our commitment to evolving software in the cloud, which we recognise as being essential to meeting the dynamic needs of modern retail," concluded Raghav.

For more information about joining Manhattan Associates, visit the company’s Careers page for a full list of available positions. Receive up-to-date product, customer and partner news directly from Manhattan Associates on X, LinkedIn and Facebook.

About Manhattan Associates

Manhattan Associates is a technology leader in supply chain and omnichannel commerce. We unite information across the enterprise, converging front-end sales with back-end supply chain execution. Our software, platform technology and unmatched experience help drive both top-line growth and bottom-line profitability for our customers.

Manhattan Associates designs, builds and delivers leading edge cloud and on-premises solutions so that across the store, through your network or from your fulfillment center, you are ready to reap the rewards of the omnichannel marketplace. For more information, please visit www.manh.com.

About The Australian Business Awards

The Australian Business Awards are an international, all-encompassing awards program honouring organisations that demonstrate the core values of business excellence, product excellence, sustainability and commercial success in their respective industries. Conducted annually and currently in their inauguration, the Awards honour the world’s industry leaders through the acknowledgment of innovative business processes, product development, enterprise, sustainability and overall business success. The Awards also recognise the important social and environmental contributions made by organisations through excellence of service, commitment to their customers, philanthropic ideals, ethical behaviour and environmental sustainability.

Source : Manhattan Associates Winner of ABA100® Supply Chain and Cloud Innovation Awards at Australian Business Awards, Second Year Running

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

LONGi will also provide solar systems and solutions, and solar energy skills training, to support refugees and host communities

DUBAI, UAE, Dec. 4, 2023 /PRNewswire/ — LONGi, a world-leading solar technology company, today announced a new three-year partnership with UNHCR, the UN Refugee Agency, to deliver impact across climate action, energy equity, and green transformation. The announcement was made at the Solar+ Pavilion during COP28, the 28th Conference of the Parties to the United Nations Framework Convention on Climate Change.

Dennis She, Vice President of LONGi, and Dominique Hyde, UNHCR’s Director of External Relations, signed the cooperation agreement at LONGi’s Solar+ Pavilion during COP28 in Dubai, UAE.

A cornerstone of the partnership is LONGi’s commitment to transform UNHCR emergency and preparedness stockpiles into solarized facilities. This will begin with a pilot project at the Regional Humanitarian Logistics Hub at the Termez Cargo Centre in Uzbekistan, which handles the rapid delivery of core relief items to countries across the region.

"When we visited the Logistics Hub in Termez with UNHCR in November, we saw first-hand the sheer magnitude of the supply work that UNHCR undertakes to serve refugees and displaced people across Asia," said Dennis She, Vice President of LONGi. "It’s an honor for LONGi to be the first partner of UNHCR to start solarizing its Logistics Hub. This agreement highlights LONGi’s dedication to driving sustainable development and we are humbled to be able to support refugee communities. Our collaboration underscores a shared commitment to fostering sustainability and resilience in the face of global challenges." 

The Regional Humanitarian Logistics Hub at the Termez Cargo Centre, Uzbekistan will be solarized through support provided by LONGi. © UNHCR/Elyor Nemat

Starting from 2024 in Pakistan, LONGi will also provide solar systems and solutions to support public facilities used by refugees and host communities to ensure safe and reliable energy that allows these communities to study, work and run their own businesses. LONGi will also work on empowering refugee and host communities with solar energy skills training to support sustainable livelihoods. This reflects this company’s desire to shoulder its social responsibility, and advance progress towards achieving Sustainable Development Goal No. 7 – Affordable and Clean Energy. 

The issue of energy inequality directly affects economic development and the quality of people’s lives. Fortunately, technological innovation has resulted in photovoltaic solutions becoming one of the most economical sources of electricity in many parts of the world. 

"We are excited about this innovative partnership which will help us improve our carbon footprint," said Dominique Hyde, UNHCR’s Director of External Relations. "Together, we can play our part in addressing the climate crisis by promoting sustainable energy solutions for everyone, especially the most vulnerable, all across the globe."

Bolstering environmental protection as part of the boarder partnership, LONGi will also support afforestation activities in Uzbekistan from 2024, to reduce environmental hazards and mitigate the impacts of extreme weather while providing income generation and employment opportunities for refugees and host communities. The three-year partnership is expected to benefit numerous countries where UNHCR implements its climate action work.  

About LONGi

Founded in 2000, LONGi is committed to being the world’s leading solar technology company, focusing on customer-driven value creation for full scenario energy transformation. Under its mission of ‘making the best of solar energy to build a green world’, LONGi is dedicated to technology innovation and has established five business sectors, covering mono silicon wafers cells and modules, commercial and industrial distributed solar solutions, green energy solutions and hydrogen equipment. The company has honed its capabilities to provide green energy and has more recently also embraced green hydrogen products and solutions to support global zero-carbon development. www.longi.com 

Source : LONGi leads the way in partnership with UNHCR to solarize its Logistics Hub

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

DUBAI, UAE, Dec. 4, 2023 /PRNewswire/ — Korea Hydro & Nuclear Power (KHNP), a state-run energy company in South Korea is presenting Korea’s nuclear solutions for accelerating a journey to a net zero future at the 28th United Nations Climate Change Conference (COP28).

Korea Hydro & Nuclear Power (KHNP) Pavilion at COP28

KHNP’s pavilion is located in the Green Zone at Expo City Dubai and showcases Korea’s innovative small modular reactor (i-SMR) technology and i-SMR powered Smart Net-Zero City (SSNC) model, which leverage the full benefits of nuclear in driving the global energy transition.

The pavilion will be open throughout the duration of the COP28 until Dec 12.

Innovative Small Modular Reacotor (i-SMR) showcased at KHNP Pavilion

KHNP’s CEO Jooho Whang presenting the i-SMR powered Smart Net-Zero City (SSNC) model

KHNP hosts a panel discussion at the KHNP Pavilion

Source : Korea Hydro & Nuclear Power Presents Innovative Nuclear Solutions for a Net-Zero Future at COP28

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

CAMBRIDGE, Mass., Dec. 3, 2023 /PRNewswire/ — Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, announced today it has entered into a collaboration agreement with Lycia Therapeutics, a leader in extracellular protein degradation.  Lycia is using its proprietary lysosomal targeting chimeras (LYTACs) platform to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to-treat diseases. Through the collaboration, Lycia will leverage Nona’s proprietary Harbour Mice® HCAb fully human antibody transgenic mice platform to discover novel antibodies for its LYTAC protein degrader therapeutics.

"We are pleased to enter into this collaboration with Lycia Therapeutics, extending our service footprint to the area of extracellular protein degradation.   We believe Lycia’s leveraging of our antibody discovery capabilities will help accelerate its efforts to advance novel protein degrader therapeutics," said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences said.

"Our LYTACs can uniquely address extracellular disease-driving targets that remain challenging for existing antibody and small molecule modalities. We look forward to deploying Nona Biosciences’ technology to advance the discovery of novel therapeutics for currently underserved patient populations," said Steve Staben, Ph.D., Chief Scientific Officer of Lycia Therapeutics.

About Nona Biosciences

Nona Biosciences (a wholly-owned subsidiary of HBM Holdings Limited, HKEX: 02142) is a global biotechnology company committed to cutting-edge technology innovation and provides a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody discovery services range from antigen preparation, animal immunization, highly robust antibody screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® technology and the experienced therapeutic antibody discovery team.

Harbour Mice® generate fully human monoclonal antibodies in a traditional two heavy and two light chain (H2L2) format, and a heavy chain only (HCAb) format. Integrating Harbour Mice® with highly robust antibody screening platforms, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit www.nonabio.com.

Source : Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

NEW DELHI, Dec. 4, 2023 /PRNewswire/ — The winners of the prestigious HR Asia Best Companies to Work for in Asia India 2023 awards have been announced by HR Asia, a leading publication in the human resources industry. In its third year, the 2023 India programme has recognised 14 outstanding organisations that have excelled in creating exemplary work environments for their employees.

Congratulations to the Winners of 2023 Hong Kong HR Asia Best Companies to Work in Asia

This year’s theme is "Celebrate Diversity, Equity and Inclusion." HR Asia has taken a significant step forward in recognising and promoting workplaces that foster diversity, equity, and inclusion by placing these values at the forefront of the selection process.

This year’s nominations saw a significant increase, with 155 companies competing for the coveted title of Best Companies to Work for in Asia India 2023. Furthermore, a staggering 2,910 survey participants shared their insights and experiences, emphasising the region’s extensive participation and engagement.

"We are thrilled to witness such overwhelming enthusiasm and support for the HR Asia Best Companies to Work for in Asia India 2023 awards," said William Ng, Editor-in-Chief of HR Asia. "The increased number of nominations and survey participants demonstrates the commitment of organisations in India to prioritise employee satisfaction and well-being."

Three new categories were added this year to reflect the organisation’s commitment to recognising excellence and innovation in the human resources domain. The HR Asia Diversity, Equity, and Inclusion Awards seek to recognise organisations that have made significant strides towards creating diverse and inclusive workplaces. The HR Asia Most Caring Company Awards recognise organisations that have demonstrated exceptional care for their employees, particularly during difficult times. Finally, the HR Asia Digital Transformation Awards recognise organisations that have successfully used technology to transform their human resource practices.

The HR Asia Best Companies to Work for in Asia India 2023 award winners have shown an unwavering dedication to employee satisfaction, welfare, and development. These organisations have set the standard for others to follow by fostering a positive work environment that promotes growth and excellence.

The award covers fourteen markets across the region including mainland China, Cambodia, Hong Kong, Indonesia, India, Japan, Korea, Macau, Malaysia, Philippines, Singapore, Thailand, United Arab Emirates, and Vietnam making this the largest recognition programme and survey in the region for employee engagement. For more information about the HR Asia Best Companies to Work for in Asia India 2023 awards and a complete list of winners, please visit https://hr.asia/awards/

LIST OF WINNERS OF HR ASIA BEST COMPANIES TO WORK FOR IN ASIA 2023 (INDIA EDITION) IN ALPHABETICAL ORDER:

A. MENARINI INDIA PVT LTD APL LOGISTICS INDIA CARGILL INDIA PVT LTD CEVA LOGISTICS INDIA PVT LTD COLLIERS INDIA CONCENTRIX DAKSH SERVICES INDIA PVT LTD DSV AIR & SEA PVT LTD EY HERSHEY INDIA PRIVATE LIMITED KONE ELEVATOR MARSH INDIA INSURANCE BROKERS PRIVATE LIMITED SKODA AUTO VOLKSWAGEN INDIA PRIVATE LIMITED TITAN COMPANY LIMITED WTW INDIA GLOBAL DELIVERY CENTER

WINNERS OF HR ASIA DIVERSITY, EQUITY & INCLUSION AWARDS 2023

APL LOGISTICS INDIA CARGILL INDIA PVT LTD

WINNERS OF HR ASIA MOST CARING COMPANY AWARDS 2023

A. MENARINI INDIA PVT. LTD CARGILL INDIA PVT LTD

About BUSINESS MEDIA INTERNATIONAL

Business Media International is a subsidiary of Audience Analytics Limited (1AZ.SG), a regional leader in promoting growth for companies in Asia through data-driven brands and initiatives. We own renowned media brands such as SME Magazine, HR Asia, Capital Asia, Energy Asia, Logistics Asia, TruthTV, and CXP Asia as well as business impact assessment brands such as SME100, HR Asia Best Companies to Work for in Asia, Golden Bull Awards and CXP Asia Best Customer Experience Awards. We organise various exhibitions and have the proprietary software-as-a-service — Total Engagement Assessment Model – in our portfolio.

Adrian Cheng
Marketing Manager
Business Media International
Mobile No.: 012-2692701
Email: [email protected] 

Source : Diversity Thrives, Inclusion Prevails: HR Asia Best Companies to Work for in Asia India 2023 Honors 14 Champions of an Inclusive Workforce

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network